Abstract

Esophageal squamous cell carcinoma (ESCC) accounts for most esophageal cancer in Asia, and is the sixth common cause of cancer-related deaths worldwide. Previous studies indicated HOXB7 is overexpressed in ESCC tissues, but data on prognostic value are limited. A total of 76 advanced ESCC cases were investigated. Immunohistochemistry (IHC) was used to detect the expression levels of HOXB7 and Kaplan-Meier curves and Cox regression models to determine prognostic significance. Stratified analysis was also performed according to lymph node (LN) status. Kaplan-Meier curve analysis indicated that HOXB7 positive patients had significantly shorter overall survival (OS) than HOXB7 negative patients. Multivariate analysis using the Cox proportional hazards model indicated only TNM stage and HOXB7 expression to be independent predictors of overall survival of advanced ESCC patients. HOXB7 indicated poor OS in both lymph node negative (LN?) and lymph node positive (LN+) patients. HOXB7 predicts poor prognosis of advanced ESCC patients and can be applied as an independent prognostic predictor.

Highlights

  • Esophageal cancer is the sixth common cause of cancer-related deaths worldwide

  • We found no significant associations between HOXB7 expression and any baseline clinicopathologic parameters of advanced Esophageal squamous cell carcinoma (ESCC) patients

  • Kaplan-Meier curve analysis suggested that the median survival time was 33.78 months for HOXB7-positive

Read more

Summary

Introduction

Esophageal cancer is the sixth common cause of cancer-related deaths worldwide. Esophageal squamous cell carcinoma (ESCC) is the major histological type of esophageal cancer (Jemal et al, 2011). Previous studies indicated HOXB7 is overexpressed in ESCC tissues, but data on prognostic value are limited. Multivariate analysis using the Cox proportional hazards model indicated only TNM stage and HOXB7 expression to be independent predictors of overall survival of advanced ESCC patients.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call